<DOC>
	<DOC>NCT00281567</DOC>
	<brief_summary>Comparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler.</brief_summary>
	<brief_title>Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis of COPD FEV1 &lt; 60% predicted FEV1 &lt; 70% of FVC Smoking history of 10 packyears Significant other disease than COPD Recent history of MI (1 year or less) Cardiac arrhythmia requiring drug therapy History of asthma, allergic rhinitis or eosinophil count &gt; 600 mm3 Symptomatic prostatic hypertrophy or bladder neck obstruction Known narrowangle glaucoma Abnormal baseline hematology, blood chemistry or urinalysis History of cancer within last 5 years Lifethreatening pulmonary obstruction Cystic fibrosis or bronchiectasis Tuberculosis Pulmonary resection</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>